Understanding the Liquidity Contract with Natixis Oddo BHF SCA
Transgene has entrusted its liquidity program to Natixis Oddo BHF SCA. As of December 31, 2024, the management of resources through this liquidity account provided insight into the efficiency and effectiveness of the program. The following resources were diligently managed:
- 359,661 shares
- €80,653.30
Operational Performance in H2 2024
During the second half of 2024, significant activity occurred in the liquidity account. A comprehensive overview of transactions showed a robust trading environment:
Purchases totaled:
- 250,777 shares
- €243,947.38 in total value
- 1,154 transactions conducted
Conversely, sales figures were notable as well:
- 229,905 shares sold
- €230,275.17 from these sales
- 1,081 transactions completed
Initial Liquidity Program Resources
It is important to trace back the resources allocated when the liquidity program was initiated in 2016. This foundational phase set up the following resources:
- €500,000.00 available at inception
Upon the transfer of the liquidity program to Natixis Oddo BHF SCA, effective January 2, 2020, the resources managed had evolved significantly:
- 164,183 shares were accounted for
- €246,158.00 in monetary resources
Keeping Stakeholders Informed
Transgene prioritizes transparency and communication with its stakeholders. For any inquiries or additional information regarding the liquidity program and its evolving strategies, stakeholders can reach out directly:
Contact Information
Transgene:
Lucie LARGUIER
CFO
+33 (0)3 88 27 91 00
Email: investorrelations@transgene.fr
Frequently Asked Questions
What is the role of Natixis Oddo BHF SCA in managing Transgene's liquidity?
Natixis Oddo BHF SCA oversees the liquidity program, managing shares and financial resources to optimize trading performance.
How many shares were managed as of December 31, 2024?
As of December 31, 2024, a total of 359,661 shares were actively managed through the liquidity account.
What were the financial metrics for purchases in H2 2024?
Total purchases amounted to 250,777 shares with a monetary value of €243,947.38, encompassing 1,154 transactions.
What resources were initially allocated to the liquidity program?
The liquidity program was established with an initial fund of €500,000.00 in 2016, setting the foundation for future management.
What are the future plans for Transgene's liquidity program?
Transgene aims to continue optimizing its liquidity management strategies to enhance performance and maximize shareholder value.